55876-84-1

Basic information

• Product Name: METHYL-5-BROMOMETHYLPYRIDINE-2-CARBOXYLATE
• Synonyms: METHYL-5-BROMOMETHYLPYRIDINE-2-CARBOXYLATE;5-(Bromomethyl)pyridine-2-carboxylic acid methyl ester;Methyl 5-(bromomethyl)picolinate;5-Bromomethyl-2-(1-methoxy-vinyl)-pyridine
• CAS NO: 55876-84-1
• Molecular Formula: C₈H₈BrNO₂
• Molecular Weight: 230.06
• Mol File: 55876-84-1.mol
• Article Data: 9

Chemical Properties

• Boiling Point: 334℃
• Flash Point: 156℃
• Appearance: /
• Density: 1.533
• Vapor Pressure: 0.000132mmHg at 25°C
• Refractive Index: 1.563
• Storage Temp.: under inert gas (nitrogen or Argon) at 2-8°C
• PKA: 0.78±0.10(Predicted)
• CAS DataBase Reference: METHYL-5-BROMOMETHYLPYRIDINE-2-CARBOXYLATE(CAS DataBase Reference)
• NIST Chemistry Reference: METHYL-5-BROMOMETHYLPYRIDINE-2-CARBOXYLATE(55876-84-1)
• EPA Substance Registry System: METHYL-5-BROMOMETHYLPYRIDINE-2-CARBOXYLATE(55876-84-1)

Safety Data

• Hazardous Substances Data: 55876-84-1(Hazardous Substances Data)

Usage

General Description

Methyl-5-bromomethylpyridine-2-carboxylate is a chemical compound with the molecular formula C9H8BrNO2. It is a derivative of pyridine and carboxylic acid, and it contains a bromomethyl and a methyl group attached to the pyridine ring. Methyl-5-bromomethylpyridine-2-carboxylate is commonly used in the synthesis of pharmaceuticals and agrochemicals due to its versatile reactivity and potential for forming new carbon-carbon and carbon-heteroatom bonds. Methyl-5-bromomethylpyridine-2-carboxylate is also utilized in research and development as a building block for creating novel organic compounds with unique properties.

InChI:InChI=1/C8H8BrNO2/c1-12-8(11)7-3-2-6(4-9)5-10-7/h2-3,5H,4H2,1H3

Upstream product

• 29681-38-7 methyl 5-methylpyridine-2-carboxylate 

Downstream Products

• 1417421-50-1 methyl 5-((3-(trifluoromethoxy)phenoxy)methyl)picolinate 
• 1417421-46-5 methyl 5-(m-tolyloxymethyl)picolinate 
• 1417421-44-3 methyl 5-((3-ethylphenoxy)methyl)picolinate 
• 1417419-77-2 C₁₇H₁₈BrFN₂O₂ 
• 1417421-51-2 5-((3-(trifluoromethoxy)phenoxy)methyl)picolinic acid 
• 1417421-49-8 5-((3-bromo-5-fluorophenoxy)methyl)picolinic acid 
• 1417421-45-4 5-((3-ethylphenoxy)methyl)picolinic acid 
• 1382991-47-0 5-(3-fluorobenzyl)picolinic acid 
• 1382991-46-9 methyl 5-(3-fluorobenzyl)picolinate 

Relevant articles and documents

PHOSPHATE DERIVATIVES AND USE THEREOF

The present invention discloses a compound with the following formula (I), or a tautomer, mesomer, racemate, enantiomer, and diastereoisomer thereof, or a mixture form thereof, or a pharmaceutically acceptable salt thereof, or a prodrug molecule thereof, wherein D is selected from: The invention further discloses the use of the compound in the preparation of drugs for preventing and/or treating cancers, and the use of the compound in the preparation of drugs for inhibiting cancer metastasis. The compound of the present invention can effectively inhibit the proliferation and metastasis of cancer cells by adjusting the acidity of a tumor microenvironment to achieve a better effect in clinical cancer treatment, and has broad application prospects.

Exploration of Structure-Activity Relationship of Aromatic Aldehydes Bearing Pyridinylmethoxy-Methyl Esters as Novel Antisickling Agents

Aromatic aldehydes elicit their antisickling effects primarily by increasing the affinity of hemoglobin (Hb) for oxygen (O2). However, challenges related to weak potency and poor pharmacokinetic properties have hampered their development to treat sickle cell disease (SCD). Herein, we report our efforts to enhance the pharmacological profile of our previously reported compounds. These compounds showed enhanced effects on Hb modification, Hb-O2 affinity, and sickling inhibition, with sustained pharmacological effects in vitro. Importantly, some compounds exhibited unusually high antisickling activity despite moderate effects on the Hb-O2 affinity, which we attribute to an O2-independent antisickling activity, in addition to the O2-dependent activity. Structural studies are consistent with our hypothesis, which revealed the compounds interacting strongly with the polymer-stabilizing αF-helix could potentially weaken the polymer. In vivo studies with wild-type mice demonstrated significant pharmacologic effects. Our structure-based efforts have identified promising leads to be developed as novel therapeutic agents for SCD.

HETEROARYL COMPOUNDS AS BTK INHIBITORS AND USES THEREOF

The present invention relates to imidazo pyridine compounds, and pharmaceutically acceptable compositions thereof, useful as BTK inhibitors.